FindTrial
Sign In

Enalapril 10 mg bid

DRUG2 trials

Sponsors

Novartis Pharmaceuticals, Vanderbilt University Medical Center

Conditions

Heart Failure NYHA Class IHeart Failure NYHA Class IIHeart Failure NYHA Class IIIHeart Failure With Reduced Ejection Fraction

Phase 2

Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2
WithdrawnNCT03005184
Vanderbilt University Medical CenterHeart Failure NYHA Class I, Heart Failure NYHA Class II, Heart Failure NYHA Class III
Start: 2017-09-30End: 2020-01-31Updated: 2018-01-11

Phase 3

This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure
TerminatedNCT01035255
Novartis PharmaceuticalsHeart Failure With Reduced Ejection Fraction
Start: 2009-12-31End: 2014-05-31Updated: 2016-08-15

Related Papers

Sacubitril/valsartan and quality of life assessed using the EuroQol Five-dimension Three-level questionnaire level sum score (EQ-5D-3L-LSS) in patients with HFrEF and HFmrEF/HFpEF.
2025-11-01
Comprehensive Analysis of the Effects of Sacubitril/Valsartan According to Sex Among Patients With Heart Failure and Reduced Ejection Fraction in PARADIGM‐HF
Journal of the American Heart Association2025-04-233 citations
Effects of Sacubitril/Valsartan According to Natriuretic Peptide Levels in Patients Enrolled in PARADIGM-HF and PARAGON-HF
JACC Heart Failure2025-03-127 citations
Effects of sacubitril/valsartan according to background beta‐blocker therapy in patients with heart failure and reduced ejection fraction: Insights from <scp>PARADIGM</scp> ‐ <scp>HF</scp>
European Journal of Heart Failure2024-11-195 citations
Visit-to-Visit Changes in Heart Rate in Heart Failure: A Pooled Participant-Level Analysis of the PARADIGM-HF and PARAGON-HF Trials
European Journal of Heart Failure2024-10-221 citations
Race in Heart Failure: A Pooled Participant-Level Analysis of the Global PARADIGM-HF and PARAGON-HF Trials.
2024-08-312 citations
Effects of Sacubitril/Valsartan on All-Cause Hospitalizations in Heart Failure
JAMA Cardiology2024-08-305 citations
Aptamer Proteomics for Biomarker Discovery in Heart Failure With Preserved Ejection Fraction: The PARAGON‐HF Proteomic Substudy
Journal of the American Heart Association2024-06-2111 citations
Sacubitril/Valsartan in Patients With Heart Failure and Deterioration in eGFR to &lt;30 mL/min/1.73 m&lt;sup&gt;2&lt;/sup&gt;.
2024-06-0510 citations
Effects of Sacubitril/Valsartan Across the Spectrum of Renal Impairment in Patients With Heart Failure.
2024-04-0615 citations
Cost Effectiveness of Dapagliflozin for Heart Failure Across the Spectrum of Ejection Fraction: An Economic Evaluation Based on Pooled, Individual Participant Data From the DELIVER and DAPA‐HF Trials
Journal of the American Heart Association2024-02-237 citations
Clinical Characteristics and Outcomes in Patients With Heart Failure: Are There Thresholds and Inflection Points in Left Ventricular Ejection Fraction and Thresholds Justifying a Clinical Classification?
Circulation2023-06-2739 citations
Importance of cystatin C in estimating glomerular filtration rate: the PARADIGM-HF trial
European Heart Journal2023-04-1320 citations
Prevalent and Incident Anemia in PARADIGM-HF and the Effect of Sacubitril/Valsartan.
2023-04-1210 citations
Variation in Renal Function Following Transition to Sacubitril/Valsartan in Patients With Heart Failure
Journal of the American College of Cardiology2023-02-2026 citations
Urinary cGMP (Cyclic Guanosine Monophosphate)/BNP (B-Type Natriuretic Peptide) Ratio, Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction: An Analysis of the PARADIGM-HF Trial
Circulation Heart Failure2023-01-258 citations
Associations Between New York Heart Association Classification, Objective Measures, and Long-term Prognosis in Mild Heart Failure
JAMA Cardiology2022-12-0738 citations
A comparison of semiparametric approaches to evaluate composite endpoints in heart failure trials
Statistics in Medicine2021-07-303 citations
Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE
Clinical Research in Cardiology2021-06-088 citations
Incidence and Outcomes of Pneumonia in Patients With Heart Failure.
2021-04-0159 citations

36 more papers not shown